Reuters logo
BRIEF-Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067
March 22, 2017 / 6:42 AM / 6 months ago

BRIEF-Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067

March 22 (Reuters) - Galapagos NV:

* Initiates Phase 1 study with novel CF potentiator GLPG3067

* Triggers a $7.5 million milestone payment from AbbVie

* Third potentiator in growing portfolio of cystic fibrosis drug candidates

* Aim of the phase 1 study is to evaluate the safety, tolerability and pharmacokinetics of oral single and multiple ascending doses of GLPG0367

* Safety and tolerability of the combination of GLPG3067 and GLPG2222 will also be evaluated.

* “we plan to initiate multiple studies within our cf portfolio in the course of this year, as we get closer to our goal of initiating a patient evaluation of a triple combination therapy by mid-2017.” - CSO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below